Acid burns from personal assault in Uganda.

J. Asaria,Olive C Kobusingye,B. Khingi,R. Balikuddembe,Manuel Gomez,Massey Beveridge,Massey Beveridge

DOI: https://doi.org/10.1016/J.BURNS.2003.08.009

IF: 2.609

2004-02-01

Burns

Abstract:

What problem does this paper attempt to address?

Amyloid β-Protein Assembly: Differential Effects of the Protective A2T Mutation and Recessive A2V Familial Alzheimer's Disease Mutation.

Xueyun Zheng,Deyu Liu,Robin Roychaudhuri,D. Teplow,M. Bowers

DOI: https://doi.org/10.1021/acschemneuro.5b00171

2015-10-21

ACS Chemical Neuroscience

Abstract:Oligomeric states of the amyloid β-protein (Aβ) appear to be causally related to Alzheimer's disease (AD). Recently, two familial mutations in the amyloid precursor protein gene have been described, both resulting in amino acid substitutions at Ala2 (A2) within Aβ. An A2V mutation causes autosomal recessive early onset AD. Interestingly, heterozygotes enjoy some protection against development of the disease. An A2T substitution protects against AD and age-related cognitive decline in non-AD patients. Here, we use ion mobility-mass spectrometry (IM-MS) to examine the effects of these mutations on Aβ assembly. These studies reveal different assembly pathways for early oligomer formation for each peptide. A2T Aβ42 formed dimers, tetramers, and hexamers, but dodecamer formation was inhibited. In contrast, no significant effects on Aβ40 assembly were observed. A2V Aβ42 also formed dimers, tetramers, and hexamers, but it did not form dodecamers. However, A2V Aβ42 formed trimers, unlike A2T or wild-type (wt) Aβ42. In addition, the A2V substitution caused Aβ40 to oligomerize similar to that of wt Aβ42, as evidenced by the formation of dimers, tetramers, hexamers, and dodecamers. In contrast, wt Aβ40 formed only dimers and tetramers. These results provide a basis for understanding how these two mutations lead to, or protect against, AD. They also suggest that the Aβ N-terminus, in addition to the oft discussed central hydrophobic cluster and C-terminus, can play a key role in controlling disease susceptibility.
Orphan drug policy analysis in China

Meilin Liu,Yanqin Lu,Junfeng Li,Yongtao Zhang,Shanshan Zhang,Yisheng Liu

DOI: https://doi.org/10.3389/fphar.2024.1278710

IF: 5.6

2024-06-14

Frontiers in Pharmacology

Abstract:Rare diseases have various types, low incidence rates, complex conditions, and are often difficult to diagnose. Due to China's large population, there is a significant number of rare disease patients, but there is a shortage of orphan drugs. Consequently, these patients often find themselves in a situation where necessary medications are either unavailable or unaffordable. To address this urgent clinical need, China has implemented a series of orphan drug policies aimed at improving drug accessibility and affordability. In terms of drug accessibility, companies are encouraged to expedite drug development through the implementation of tax incentives, guidance for clinical research on rare diseases, and the provision of data protection periods of 6 years, along with market exclusivity periods limited to a maximum of 7 years. Moreover, exemptions for clinical trials, acceptance of overseas clinical trial data, and the creation of a list prioritizing clinically urgent new drugs from overseas have been introduced to expedite the drug registration application, review, inspection, and approval processes. In terms of drug affordability, the import value-added tax on rare disease drugs has been reduced by 3%, and various provinces and cities have established a representative rare disease protection model, which includes special funds, medical assistance programs, and serious disease insurance. The national medical insurance catalog has been adjusted to reduce the financial burden on rare disease patients, resulting in an increase in the number of orphan drugs covered by the catalog to 95 as of March 2024. By comparing orphan drug policies in the United States, the European Union, Japan, Australia, and other countries (or regions), we will provide relevant suggestions to further improve orphan drug policies in China, thus bringing more treatment options and hope to patients with rare diseases.

pharmacology & pharmacy
A Cross-National Comparative Study of Orphan Drug Policies in the United States, the European Union, and Japan: Towards a Made-in-china Orphan Drug Policy.

Bao-cheng Liu,Lin He,Guang He,Yun He

DOI: https://doi.org/10.1057/jphp.2010.30

IF: 3.526

2010-01-01

Journal of Public Health Policy

Abstract:Rare diseases can severely impact patient life quality as well as impose a serious burden on society. But research and development for drugs to treat these disorders has stagnated because of lack of demand, insufficient knowledge of pathophysiological mechanisms, and too few patients for clinical trials. In several countries – the United States, the EU, and Japan – specific legislation has been enacted to encourage pharmaceutical companies to expedite the development of drugs for rare diseases, orphan drugs, and to assure access to them. We analyze the strengths and weaknesses of the incentives in these laws and describe the status of rare diseases in China. We offer some recommendations for orphan drug legislation in China, based on local research on rare diseases.
How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017

Xiaodong Guan,Jingyuan Zhang,Chunxia Man,Bingyu Ni,Luwen Shi

DOI: https://doi.org/10.1016/j.xphs.2019.01.012

IF: 3.8

2019-01-01

Journal of Pharmaceutical Sciences

Abstract:Rare diseases are an important global public health issue. One significant challenge is to ensure the access to orphan drugs for patients with rare disease. This study aims to evaluate the accessibility of orphan drugs in China. Information pertaining to the availability and costs of each orphan drug in each hospital was obtained from the Chinese Medicine Economic Information database during 2011-2017. We measured the accessibility of orphan drugs from 3 aspects: availability, daily costs, and affordability to patients.The market availability rate of orphan drugs in China was 28.8% by June 30, 2017. The median availability rate at the hospital level was less than 15% but was increasing over time. The cost of a defined daily dose of orphan drugs varied significantly with a decreasing trend in all areas. Less than half of all surveyed orphan drugs had a cost of a defined daily dose no more than residents' average daily income.This study reveals the challenges of access to orphan drugs in China. The availability of marketed orphan drugs in China was relatively low and most orphan drugs placed a heavy financial burden on patients with rare disease. It is necessary to develop legislation for orphan drugs and encourage domestic generics.
Pharmaceutical policy and innovation for rare diseases: A narrative review

Adrián Alonso Ruiz,Kaitlin Large,Suerie Moon,Marcela Vieira

DOI: https://doi.org/10.12688/f1000research.130809.2

2023-11-13

Abstract:This article aims to synthesize the existing literature on the implementation of public policies to incentivize the development of treatments for rare diseases, (diseases with very low prevalence and therefore with low commercial interest) otherwise known as orphan drugs. The implementation of these incentives in the United States (US), Japan, and in the European Union (EU) seems to be related to a substantial increase in treatments for these diseases, and has influenced the way the pharmaceutical research & development (R&D) system operates beyond this policy area. Despite the success of the Orphan Drug model, the academic literature also highlights the negative implications that these public policies have on affordability and access to orphan drugs, as well as on the prioritization of certain disease rare areas over others. The synthesis focuses mostly on the United States' Orphan Drug Act (ODA) as a model for subsequent policies in other regions and countries. It starts with a historical overview of the creation of the term "rare diseases", continues with a summary of the evidence available on the US ODA's positive and negative impacts, and provides a summary of the different proposals to reform these incentives in light of the negative outcomes described. Finally, it describes some key aspects of the Japanese and European policies, as well as some of the challenges captured in the literature related to their impact in Low- and Middle-Income Countries (LMICs).
Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications

Zhiyao Zhao,Zhongyang Pei,Anxia Hu,Yuhui Zhang,Jing Chen

DOI: https://doi.org/10.1186/s13023-023-02684-8

2023-07-27

Orphanet Journal of Rare Diseases

Abstract:Abstract Objectives Rare diseases are a global public health issue with a more pressing situation in China. Unfortunately, the relevant research and development in this country are still in its infancy, leading to limited drug accessibility. In view of this, the Chinese government has taken a series of countermeasures to promote orphan drug R&D in recent years, which has presented encouraging results. This paper aims to review incentive policies and funding initiatives formulated by the Chinese government and examine their implications on orphan drug R&D. Methods Policies targeting orphan drug R&D during 2012–2022 were retrieved from the relevant official websites, categorized into different themes and analyzed for the contents. Data on government funding, drug approval, clinical trial approval and orphan drug designation were collected through internet search to analyze the implications of those incentive policies and initiatives on orphan drug R&D in China. Results A total of 20 relevant policy documents were identified and five major themes were revealed through content analysis, including national strategy, expedited approval, safety and efficacy requirements, data protection and technical support. The government input in orphan drug R&D has witnessed a steady annual increase. Driven by those incentives, the numbers of orphan drugs approved for marketing and drug candidates entering clinical studies are increasing year by year, and more domestic pharmaceutical companies are actively involved in the R&D of orphan drugs. Conclusions Orphan drug development in China is growing rapidly under the stimulation of incentive regulatory policies and more investment in researches. China is working toward a more standardized and comprehensive rare disease ecosystem. However, there are still some challenges, such as the lack of sufficient financial support and the call for systematic legislation on rare diseases, to be addressed for future success.

genetics & heredity,medicine, research & experimental
The availability and affordability of orphan drugs for rare diseases in China

Shiwei Gong,Yingxiao Wang,Xiaoyun Pan,Liang Zhang,Rui Huang,Xin Chen,Juanjuan Hu,Yi Xu,Si Jin

DOI: https://doi.org/10.1186/s13023-016-0392-4

2016-02-27

Abstract:Background: Orphan drugs are intended to treat, prevent or diagnose rare diseases. In recent years, China healthcare policy makers and patients have become increasingly concerned about orphan drug issues. However, very few studies have assessed the availability and affordability of orphan drugs for rare diseases in China. The aim of this study was to provide an overview of the availability and affordability of orphan drugs in China and to make suggestions to improve patient access to orphan drugs. Methods: Two components of the availability of orphan drugs were examined. Market availability was assessed by the extent to which orphan drugs were marketed in China with a comparison to orphan drugs in international markets, such as the U.S., EU and Japan. We conducted surveys and collected data from 24 tertiary public hospitals in China to measure hospital-level availability of orphan drugs. The affordability of orphan drugs was calculated using hospital dispensary prices and was expressed as days of average daily income required for the cost of a course of treatment. Affordability was also analyzed under the Chinese basic medical insurance system. Results: Orphan drugs approved in the U.S., EU and Japan had 37.8%, 24.6% and 52.4% market availability in China, respectively. Median availability of 31 orphan drugs surveyed at the 24 tertiary public hospitals was 20.8% (very low). Within a periodic treatment course, the average treatment cost of 23 orphan drugs is approximately 4, 843. 5 USD, which equates to 505.6 days of per capita net income for an urban resident with a middle income (187.4 days for a high-income urban resident) or 1,582.8 days's income for a rural resident with a middle income (657.2 days for a high-income rural resident). Except for homoharringtonine, 22 orphan drugs for 14 rare diseases were unaffordable for the most of residents in China. With 5% out-of-pocket expenses, only three generics could be afforded by middle-income residents, whereas seven drugs for high-income urban residents. Conclusions: The Chinese government can take more responsibility for improving the availability and affordability of orphan drugs through setting up incentive policies and public platforms for sharing of orphan drug information. Control of the high price of orphan drugs, combined with a joint funding model from both government and private enterprise can efficiently reduce the economic burden of affected patients in China.
Orphan drug development: The impact of regulatory and reimbursement frameworks

Yu-Jun Huang,Wan-Yu Chao,Chi-Chuan Wang,Lin-Chau Chang

DOI: https://doi.org/10.1016/j.drudis.2022.03.002

IF: 8.369

2022-03-01

Drug Discovery Today

Abstract:The enactment of orphan drug-specific legislation pioneered by the USA was subsequently followed by many regions, including the European Union (EU), Australia, Japan, and Taiwan. Here, we discuss the associated regulations established and their impacts in the aforementioned regions, which are among the first with frameworks specific for orphan drugs. Varied scopes of rare diseases or orphan drugs, diverse incentives, and heterogeneous types of reimbursement systems imply the prioritization of the agencies concerned. The numbers of designated and approved drugs reflect the impact of the regulatory and reimbursement frameworks. A comparison of the frameworks and their impact in the respective regions could provide valuable information for developing and improving related frameworks for countries worldwide.

pharmacology & pharmacy
Review of 11 national policies for rare diseases in the context of key patient needs

Safiyya Dharssi,Durhane Wong-Rieger,Matthew Harold,Sharon Terry

DOI: https://doi.org/10.1186/s13023-017-0618-0

2017-03-31

Orphanet Journal of Rare Diseases

Abstract:Rare diseases collectively exert a global public health burden in the severity of their manifestations and the total number of people they afflict. For many patients, considerable barriers exist in terms of access to appropriate care, delayed diagnosis and limited or non-existing treatment options. Motivated by these challenges, the rare disease patient community has played a critical role, elevating the patient voice and mobilizing legislation to support the development of programs that address the needs of patients with rare diseases.The US Orphan Drug Act of 1983 served as a key milestone in this journey, providing a roadmap for other countries to introduce and implement similar orphan drug legislation; more recently, the European Union (EU) has gone further to encourage the widespread adoption and implementation of rare disease plans or strategies designed to more adequately address the comprehensive needs of patients with rare diseases. Despite these legislative efforts and the growing contributions of patient advocacy groups in moving forward implementation and adoption of rare disease programs, gaps still exist across the policy landscape for several countries. To gain deeper insights into the challenges and opportunities to address key needs of rare disease patients, it is critical to define the current status of rare disease legislation and policy across a geographically and economically diverse selection of countries. We analyzed the rare disease policy landscape across 11 countries: Germany, France, the United Kingdom, Canada, Bulgaria, Turkey, Argentina, Mexico, Brazil, China, and Taiwan. The status and implementation of policy was evaluated for each country in the context of key patient needs across 5 dimensions: improving coordination of care, diagnostic resources, access to treatments, patient awareness and support, and promoting innovative research. Our findings highlight the continuing role of the patient community in driving the establishment and adoption of legislation and programs to improve rare disease care. Further, we found that while national rare disease plans provide important guidance for improving care, implementation of plans is uneven across countries. More research is needed to demonstrate the effect of specific elements of rare disease plans on patient outcomes.

genetics & heredity,medicine, research & experimental
Orphan Drugs: The Current Situation in the United States, Europe, and Asia

Abbey S. Meyers

DOI: https://doi.org/10.1177/009286159703100115

1997-01-01

Drug Information Journal

Abstract:The American Orphan Drug Act has spurred international activities on orphan disease research and orphan drug research and development (R&D). Legislation has been enacted in Singapore and Japan, and is pending in Europe. Rare disease research facilities and information centers are operational in Scandinavia and Europe, facilitating the needs of patients, families, and medical personnel. Yet, the absence of a harmonized international orphan drug development program still hinders the wise use of economic and human resources in the most optimal and efficient manner.
Orphan drug development: Challenges, regulation, and success stories

Narendra Chirmule,Huije Feng,Esha Cyril,Vihang Vivek Ghalsasi,Mohua Chakraborty Choudhury

DOI: https://doi.org/10.1007/s12038-024-00425-y

2024-02-20

Journal of Biosciences

Abstract:Rare diseases, also known as orphan diseases, are diseases with low occurrence in the population. Developing orphan drugs is challenging because of inadequate financial and scientific resources and insufficient subjects to run clinical trials. With advances in genome sequencing technologies, emergence of cell and gene therapies, and the latest developments in regulatory pathways, some orphan drugs that have curative potential have been approved. In India, due to its large population and resource crunch, developing orphan drugs is phenomenally challenging. After adopting the Orphan Drug Act, the US-FDA has continuously made advances in regulatory pathways for orphan drugs. Particularly, n-of-one clinical trials have been successful in some cases. India has recently adopted policies that have impacted the long-neglected rare-disease ecosystem; however, there is no clear regulatory path for orphan drug development in India. We have proposed a multi-pronged approach involving close collaboration between the government, regulatory bodies, industries, and patient advocacy groups to boost orphan drug development in India. We believe that rapidly evolving technologies and business models can enable better and faster development of novel orphan drugs in India and other resource-constrained countries.

biology
Navigating health policies and programs in India: exploring opportunities to improve rare disease management and orphan drug research

Sangita Mishra,Deepa Bhat,M. P. Venkatesh

DOI: https://doi.org/10.1186/s13023-024-03377-6

2024-12-01

Orphanet Journal of Rare Diseases

Abstract:Rare disease (RD) management and orphan drug development in India face various hurdles regarding the implementation and adoption of comprehensive policies, lack of dedicated regulatory frameworks, and absence of epidemiological data. Current rare disease policy focuses more on strengthening the diagnostics and lacks a proper comprehensive treatment framework to ensure favorable clinical outcomes. Indian patients are largely excluded from global orphan drug clinical trials. This further alienates patients from access to rare disease treatment and available treatments come at high cost. This review-based study assesses the landscape of health policies and programs in India through a review of literature and guidelines, to identify strategic opportunities and recommendations for enhancing the overall care and support for the Rare Disease (RD) patient population and improving the orphan drug research ecosystem in India.

genetics & heredity,medicine, research & experimental
HTA criteria adopted in different models of public healthcare systems for orphan drugs: a scoping review

Arturo Felippini,Luiza Vasconcelos Biglia,Tácio de Mendonça Lima,Patricia Melo Aguiar

DOI: https://doi.org/10.1016/j.healthpol.2024.105080

IF: 3.255

2024-05-08

Health Policy

Abstract:Access to drugs for rare diseases constitutes a challenge to healthcare systems, especially those with public funding. This study aimed to map and summarize the criteria used by HTA agencies in different healthcare systems to evaluate reimbursement recommendations for orphan drugs. A comprehensive literature search was performed on the databases PubMed, LILACS, Scopus, and Embase and the gray literature (Google Scholar and websites of HTA agencies). Publications addressing the criteria used by HTA agencies in countries with public healthcare systems when evaluating reimbursement recommendations for orphan drugs were included. This scoping review included 23 studies published between 2014 and 2023, mostly consisting of reviews of HTA reports, guidance documents, and original articles. The criteria were mapped from 19 countries and ranked within three models of healthcare systems (National Health System, National Health Insurance, and Social Health Insurance). All models shared concerns about unmet needs and disease nature. In addition, NHS countries (e.g., United Kingdom, Sweden, and Italy) prioritized innovation and system-level impact, while SHI countries (e.g., Germany, France, the Netherlands) usually valued budget impact and employed expedited evaluation processes. This review provides a comprehensive understanding of the general tendencies of each healthcare system model in establishing differentiated criteria to address the challenges posed by the limited evidence and investment in the field of rare diseases.

health care sciences & services,health policy & services
FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis

Thomas Michaeli,Hendrik Jürges,Daniel Tobias Michaeli

DOI: https://doi.org/10.1136/bmj-2022-073242

2023-05-09

BMJ

Abstract:Abstract Objective To analyze the US Food and Drug Administration (FDA) approval, trials, unmet needs, benefit, and pricing of ultra-rare ( 200 000 citizens) orphan cancer drug indications and non-orphan cancer drug indications. Design Cross sectional analysis. Setting Data from Drugs@FDA, FDA labels, Global Burden of Disease study, and Medicare and Medicaid. Population 170 FDA approved drugs across 455 cancer indications between 2000 and 2022. Main outcome measures Comparison of non-orphan and ultra-rare, rare, and common orphan indications regarding regulatory approval, trials, epidemiology, and price. Hazard ratios for overall survival and progression-free survival were meta-analyzed. Results 161 non-orphan and 294 orphan cancer drug indications were identified, of which 25 were approved for ultra-rare diseases, 205 for rare diseases, and 64 for common diseases. Drugs for ultra-rare orphan indications were more frequently first in class (76% v 48% v 38% v 42%; P<0.001), monotherapies (88% v 69% v 72% v 55%; P=0.001), for hematologic cancers (76% v 66% v 0% v 0%; P<0.001), and supported by smaller trials (median 85 v 199 v 286 v 521 patients; P<0.001), of single arm (84% v 44% v 28% v 21%; P<0.001) phase 1/2 design (88% v 45% v 45% v 27%; P<0.001) compared with rare and common orphan indications and non-orphan indications. Drugs for common orphan indications were more often biomarker directed (69% v 26% v 12%; P<0.001), first line (77% v 39% v 20%; P<0.001), small molecules (80% v 62% v 48%; P<0.001) benefiting from quicker time to first FDA approval (median 5.7 v 7.1 v 8.9 years; P=0.02) than those for rare and ultra-rare orphan indications. Drugs for ultra-rare, rare, and common orphan indications offered a significantly greater progression-free survival benefit (hazard ratio 0.53 v 0.51 v 0.49 v 0.64; P<0.001), but not overall survival benefit (0.50 v 0.73 v 0.71 v 0.74; P=0.06), than non-orphans. In single arm trials, tumor response rates were greater for drugs for ultra-rare orphan indications than for rare or common orphan indications and non-orphan indications (objective response rate 57% v 48% v 55% v 33%; P<0.001). Disease incidence/prevalence, five year survival, and the number of available treatments were lower, whereas disability adjusted life years per patient were higher, for ultra-rare orphan indications compared with rare or common indications and non-orphan indications. For 147 on-patent drugs with available data in 2023, monthly prices were higher for ultra-rare orphan indications than for rare or common orphan indications and non-orphan indications ($70 128 (£55 971; €63 370) v $33 313 v $16 484 v $14 508; P<0.001). For 48 on-patent drugs with available longitudinal data from 2005 to 2023, prices increased by 94% for drugs for orphan indications and 50% for drugs for non-orphan indications on average. Conclusions The Orphan Drug Act of 1983 incentivizes development of drugs not only for rare diseases but also for ultra-rare diseases and subsets of common diseases. These orphan indications fill significant unmet needs, yet their approval is based on small, non-robust trials that could overestimate efficacy outcomes. A distinct ultra-orphan designation with greater financial incentives could encourage and expedite drug development for ultra-rare diseases.

medicine, general & internal
Ethical Questions Linked to Rare Diseases and Orphan Drugs - A Systematic Review

Jaroslav Kacetl,Petra Marešová,Raihan Maskuriy,Ali Selamat

DOI: https://doi.org/10.2147/RMHP.S260641

2020-10-13

Abstract:Background: Rare or orphan diseases have become an important target of healthcare activities all over the world. The study aims to identify ethical questions linked to rare diseases and orphan drugs and ethical principles or approaches applied to solve them. Methods: Relevant peer-reviewed articles were identified by means of a systematic review. The literature was searched from 20 May 2020 to 20 June 2020. The search included the databases PubMed, Scopus and Web of Science (2010 - April 2020). A total of 4,139 papers related to rare diseases were identified; with 1,205 papers obtained from Scopus; 2,476 papers from PubMed; and 458 from Web of Science with keyword search "ethics" AND "rare" AND "disease", "ethical" AND "orphan", "ethical" AND "orphan" AND "drug", and "ethical" AND "rare" AND "disease". Finally, XX studies were chosen for further analysis. Results: The main findings reveal five main ethical issues. The most essential one shows that funding research and development in the field of orphan drugs poses an almost impossible dilemma. Other issues include the significance of non-economic values like compassion and beneficence in decision-making related to orphan drugs and rare diseases; the identification of limits to labelling diseases as rare; barriers to global, supranational and international cooperation; and last but not least, determining and establishing panels of decision-makers. Conclusions: A strictly global approach would be the most appropriate way to deal with rare diseases. Nonetheless, international, let alone global, cooperation seems to be completely beyond the reach of the current international community, although the EU, for instance, has a centralized procedure for labelling orphan drugs. This deficit in international cooperation can be partly explained by the fact that the current technologically globalized world still lacks globally accepted ethical values and rules. This is further aggravated by unresolved international and intercultural conflicts. In addition, the sub-interests of various parties as well as the lack of desire to deal with other people's problems need to be taken into account. The aforementioned problems are difficult to avoid. Nevertheless, let us be cautiously optimistic. At least, there are people who raise ethical questions about rare diseases and orphan drugs.
Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries

Szczepan Jakubowski,Pawel Kawalec,Przemyslaw Holko,Iwona Kowalska-Bobko,Maria Kamusheva,Guenka Petrova,Pero Draganić,Leos Fuksa,Agnes Männik,Fanni Ispán,Vitalis Briedis,Ioana Bianchi,Marian Sorin Paveliu,Tomas Tesar

DOI: https://doi.org/10.3389/fphar.2024.1369178

IF: 5.6

2024-03-09

Frontiers in Pharmacology

Abstract:Objectives: The aim of this study was to characterize the reimbursement policy for orphan drugs (ODs) in Central and Eastern European (CEE) countries in relation to the availability and impact of clinical evidence, health technology assessment (HTA) procedure, selected economic indicators, and the drug type according to indications. Materials and methods: A list of authorized medicines with orphan designation and information about active substance, Anatomical Therapeutic Chemical (ATC) classification, and therapeutic area was extracted from the web-based register of the European Medicines Agency (EMA). A country-based questionnaire survey was performed between September 2021 and January 2022 in a group of selected experts from nine CEE countries (an invitation was sent to 11 countries). A descriptive and statistical analysis was conducted to determine statistical significance, correlations, between the drug or country characteristic and the positive recommendation or reimbursement of ODs Results: The proportion of reimbursed orphan drugs differed between countries, ranging from 17.7% in Estonia to 49.6% in Hungary ( p < 0.001). The odds that ODs were reimbursed were reduced in countries with a "strong" level of impact of drug safety and efficacy on reimbursement decisions ( p =0.018), the presence of other additional specific clinical aspects (e.g., genomic data) considered in the reimbursement decision ( p < 0.001) and mandatory (without exception) safety assessments ( p =0.004). The probability that ODs were reimbursed was increased in countries with a "moderate" level of impact of drug safety and efficacy on reimbursement decisions ( p =0.018), when reimbursement decisions are dependent on the EMA registration status and orphan drug designation ( p < 0.001), the presence of the "positive HTA recommendation guarantees reimbursement" policy ( p < 0.001), higher GDP per inhabitant ( p =0.003), and higher healthcare expenditure ( p < 0.001). Conclusion: We found that there are differences among CEE countries in the reimbursement of orphan drugs, and we identified aspects that may influence these differences. Safety, efficacy, and specific clinical aspect issues significantly influenced reimbursement decisions. Antineoplastic and immunomodulating agents drugs were the largest group of ODs and increased the chance of getting a positive recommendation. The higher GDP per inhabitant and healthcare expenditures per inhabitant were positively linked to the chance that an OD receives reimbursement.

pharmacology & pharmacy
Analysis of marketed orphan drugs in China

Wei Zhi,Meilin Liu,Dan Yang,Shanshan Zhang,Yanqin Lu,Jinxiang Han

DOI: https://doi.org/10.5582/irdr.2023.01030

2023-01-01

Intractable & Rare Diseases Research

Abstract:In recent years, China has increased attention on the issue of rare diseases, and the government has promulgated rare disease-related policies to gradually improve rare disease diagnosis, treatment, drug marketing, and patient burden. Orphan drugs were added to the medical insurance directory in 7 batches, of which 22 drugs were first included in the 2004 medical insurance directory and 8, 16, 12, 7, 8, and 7 were included in the 2009, 2017, 2019, 2020, 2021, and 2022 versions, respectively. Currently, 106 orphan drugs are marketed in China, which are suitable for treating 53 rare diseases such as hematologic diseases, congenital metabolism disorders, neuropathies, and digestive system diseases and for other treatment fields. The drugs are mainly manufactured in 15 countries such as China, Switzerland, and the USA, of which 10 drugs can be used to treat different rare diseases. At the same time, there are multiple treatments available for 25 rare diseases. In this paper, we examined the manufacturers, marketing status, indications, and inclusion of orphan drugs in the National Basic Medical Insurance Directory to describe and analyze the current status of 106 orphan drugs that are currently marketed in China to provide a reference for rare disease policy formulation and drug development.

English Else
Difficulty in detecting reperfusion injury increment in oxidative stress among patients with primary Raynaud's phenomenon and systemic sclerosis.

A. Herrick,F. Rieley,J. Braganza,M. Jayson

1995-02-01

Abstract:
Influencing Factors of Health Technology Assessment to Orphan Drugs: Empirical Evidence in England, Scotland, Canada, and Australia

Na Zhou,Hong Ji,Zheng Li,Jun Hu,Jia-Hua Xie,Yu-Heng Feng,Ni Yuan

DOI: https://doi.org/10.3389/fpubh.2022.861067

IF: 5.2

2022-06-17

Frontiers in Public Health

Abstract:This study summarizes the intrinsic criteria for the recommendation of orphan drugs in England, Scotland, Canada, and Australia with the aim of understanding the rationale for the variability in decision-making and to provide a reference for the establishment of criteria in the process of access to health insurance for orphan drugs in different countries and the construction of national uniform criteria. A comparative analysis of 60 health technology assessment (HTA) guidelines of 15 drug-indication pairs appraised by four countries (England, Scotland, Canada, and Australia) from 2017 to 2018 was done, including an in-depth analysis of a case study. Agreement levels were measured using kappa scores. Associations were explored through correspondence analysis. The four countries possess some homogeneity in the assessment, but each has its own preferences. Poor agreement exists between England, Scotland, and Canada (−0.41 < kappa score < 0.192). In the correspondence analysis, England placed more emphasis on treatment methods in terms of control type when making recommendations. Canada and Scotland focused more on trial type with Canada placing more emphasis on phase III and open-label trials and on cost-utility analysis, while Australia was less studied in terms of economic models. Different countries have different goals when establishing HTA decisions for orphan drugs due to their different degrees of orphan drug coverage. Different countries should not only combine their unique values of clinical benefit and cost-effectiveness in the assessment of orphan drugs but also give different weights during the HTA process, after considering account the development of the country itself.

public, environmental & occupational health
Analysis and Comparison of Foreign and Domestic Orphan Drug Registration Policies

XIN Xiao-xiong,GUAN Xiao-dong,CHEN Jing,SHI Lu-wen

DOI: https://doi.org/10.11669/cpj.2013.15.023

2013-01-01

Abstract:OBJECTIVE To learn from several developed countries and regions about their experience of orphan drug registration management and to explore appropriate orphan drug registration policy for China.METHODS The orphan drug registration policies of America,Japan,EU,Australia and Taiwan were analyze and compared,and the history and current situation of the orphan drug registration in China were summarized.RESULTS It has been a common trend in the world to use"designation of drugs + market approval"pattern for orphan drug registration,which has promoted the development of orphan drugs and increased the accessibility of orphan drugs in the above-mentioned countries and regions.CONCLUSION Related government departments in China should learn the advanced experience and establish our orphan drug system as soon as possible,at the same time,we should keep improving the orphan drug registration policy in China.

Acid burns from personal assault in Uganda.

Amyloid β-Protein Assembly: Differential Effects of the Protective A2T Mutation and Recessive A2V Familial Alzheimer's Disease Mutation.

Orphan drug policy analysis in China

A Cross-National Comparative Study of Orphan Drug Policies in the United States, the European Union, and Japan: Towards a Made-in-china Orphan Drug Policy.

How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017

Pharmaceutical policy and innovation for rare diseases: A narrative review

Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications

The availability and affordability of orphan drugs for rare diseases in China

Orphan drug development: The impact of regulatory and reimbursement frameworks

Review of 11 national policies for rare diseases in the context of key patient needs

Orphan Drugs: The Current Situation in the United States, Europe, and Asia

Orphan drug development: Challenges, regulation, and success stories

Navigating health policies and programs in India: exploring opportunities to improve rare disease management and orphan drug research

HTA criteria adopted in different models of public healthcare systems for orphan drugs: a scoping review

FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis

Ethical Questions Linked to Rare Diseases and Orphan Drugs - A Systematic Review

Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries

Analysis of marketed orphan drugs in China

Difficulty in detecting reperfusion injury increment in oxidative stress among patients with primary Raynaud's phenomenon and systemic sclerosis.

Influencing Factors of Health Technology Assessment to Orphan Drugs: Empirical Evidence in England, Scotland, Canada, and Australia

Analysis and Comparison of Foreign and Domestic Orphan Drug Registration Policies